

Rheumatoid Arthritis

## Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

**Trial Status**  
Completed

**Trial Runs In**  
6 Countries

**Trial Identifier**  
NCT02573012 2014-004673-16  
MA29585

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This Phase IIIb/IV, two-arm, randomized, double-blind, placebo-controlled, parallel-group, international, multicenter trial compares the change in disease activity (as assessed by Disease Activity Score in 28 joints [DAS28] erythrocyte sedimentation rate [ESR]) from randomization to Week 24 post-randomization, in participants with stable low disease activity [LDA] (DAS28 ESR score less than or equal to [ $\leq$ ] 3.2) who receive tocilizumab, and have been randomized to either continue or taper prednisone in a double-blinded fashion.

**Hoffmann-La Roche**  
Sponsor

**Phase 4**  
Phase

---

**NCT02573012 2014-004673-16 MA29585**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
 $\geq$  18 Years

**Healthy Volunteers**  
No

---